Research programme: curcumin formulations - Signpath Pharma

Drug Profile

Research programme: curcumin formulations - Signpath Pharma

Alternative Names: Diferuloylmethane formulations - Signpath Pharma; Extended-release PLGA-curcumin; Nano curcumin; Nanocurc; PLGA-liposomal-curcumin; Polylactic coglycolic acid liposomal curcumin; Polymeric nanocurcumin

Latest Information Update: 19 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins Medical Institutions; University of North Texas Health Science Center
  • Developer Signpath Pharma
  • Class Catechols
  • Mechanism of Action Inflammation mediator modulators; NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Toll-like receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Diabetic complications; Neurodegenerative disorders

Most Recent Events

  • 09 Apr 2015 Signpath Pharma has patent protection for curcumin liposomal in USA (Signpath Pharma form 10-K, April 2015)
  • 30 Dec 2011 Preclinical trials in Diabetic complications (prevention) in USA (SC)
  • 30 Dec 2011 Preclinical trials in Neurodegenerative disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top